Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients

• DOI: 10.1016/j.ctarc.2024.100839
• Publication Date: 2024-08-24T05:27:48Z
• Authors: Francesca Parisi; Giuseppa De Luca; Manuela Mosconi; Sonia Lastraioli; Chiara Dellepiane; Giovanni Rossi; Silvia Puglisi; Elisa Bennicelli; Giulia Barletta; Lodovica Zullo; Sara Santamaria; Marco Mora; Alberto Ballestrero; Fabrizio Montecucco; Andrea Bellodi; Lucia Del Mastro; Matteo Lambertini; Emanuela Barisione; Giuseppe Cittadini; Elena Tagliabue; Francesco Spagnolo; Marco Tagliamento; Simona Coco; Mariella Dono; Carlo Genova
• Keywords: Liquid biopsy; Front line

Molecular characterization is pivotal for managing non-small cell lung cancer (NSCLC), although this process often time-consuming and patients' conditions might worsen while molecular analyses are processed. Our primary aim was to evaluate the performance of "up-front" next-generation sequencing (NGS) through liquid biopsy (LB) hospitalized patients with newly detected neoplasm in parallel conventional diagnosis. The secondary included longitudinal monitoring LB oncogenic alterations at baseline. We enrolled 47 consecutive immediately after hospitalization radiological detection symptomatic neoplasm. from peripheral blood performed baseline, (CB), when feasible. Additionally, LBs were repeated during treatment actionable gene Oncomine™ Lung cfTNA Research Assay panel employed processing plasma samples NGS. enrolled. identified 28 alterations, including mutations EGFR (n = 7), KRAS 12), ERBB2 1), TP53 2), BRAF one ALK rearrangement, 4 combined involving EGFR, PIK3CA. CB consistent, except two patients. Three positive drivers did not undergo due contraindications. Median time results significantly lower compared report (11 versus 22 days, p < 0.001). Despite limited numbers, our study supports role front-line improving management cancer, potentially leading early targeted therapy initiation.